TrialBreast cancer research : BCR2023

XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.

Peter Schmid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.